Efficacy and safety profile of glimepiride in Mexican American patients with type 2 diabetes mellitus: A randomized, placebo-controlled study

Clinical Therapeutics

Volumn 25, Issue 1, 2003, Pages 194-209

  Bautista, J Luis ^a   Bugos, Christine ^b   Dirnberger, George ^c   Atherton, Tracy ^b  

^a Bautista Medical Group   (United States)

^b SANOFI   (France)

^c IQVIA   (United States)

Author keywords

Fasting plasma glucose; Glimepiride; Mexican American; Randomized trial; Type 2 diabetes

Indexed keywords

FIBRINOGEN; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR; SULFONYLUREA;

ADULT; AGED; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ETHNIC GROUP; EXERCISE; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INFECTION; INSULIN BLOOD LEVEL; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SINUSITIS; SOMNOLENCE; STROKE; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; VERTIGO; WEIGHT GAIN;

EID: 0037279862     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)90025-7     Document Type: Article

References (40)

1. Self-reported prevalence of diabetes among Hispanics - United States, 1994-1997. MMWR Morb Mortal Wkly Rep. 1999;48:8-12.
2. Diehl AK, Stern MP Special health problems of Mexican-Americans: Obesity, gallbladder disease, diabetes mellitus, and cardiovascular disease. Adv Intern Med. 1989;34:73-96.
3. Espino DV, Palmer RE Mouton CP, et al, for the Established Population for the Epidemiologic Study of the Elderly. Patterns of prescription drug utilization in elder Mexican Americans: Results from the Hispanic EPESE Study. Ethn Dis. 2000;10:218-223.
4. Burke JP, Williams K, Gaskill SP, et al. Rapid rise in the incidence of type 2 diabetes from 1987 to 1996: Results from the San Antonio Heart Study. Arch Intern Med. 1999;159:1450-1456.
5. Black SA, Ray LA, Markides KS. The prevalence and health burden of self-reported diabetes in older Mexican Americans: Findings from the Hispanic Established Populations for Epidemiologic Studies of the Elderly. Am J Public Health. 1999;89:546-552.
6. Haffner SM, Fong D, Stern MP, et al. Diabetic retinopathy in Mexican Americans and non-Hispanic whites. Diabetes. 1988;37:878-884.
7. Haffner SM, Mitchell BD, Pugh JA, et al. Proteinuria in Mexican Americans and non-Hispanic whites with NIDDM. Diabetes Care. 1989;12:530-536.
8. Harris MI, Klein R, Cowie CC, et al. Is the risk of diabetic retinopathy greater in non-Hispanic black and Mexican Americans than in non-Hispanic whites with type 2 diabetes? A US population study. Diabetes Care. 1998;21:1230-1235.
9. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-117.
10. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
11. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-865.
12. Van der Does FEE, De Neeling JND, Snoek FJ, et al. Symptoms and well-being in relation to glycemic control in type II diabetes. Diabetes Care. 1996;19:204-210.
13. Andersson DKG, Svärdsudd K. Long-term glycemic control relates to mortality in type II diabetes. Diabetes Care. 1995;18:1534-1543.
14. American Diabetes Association Clinical Practice Recommendations 2001. Diabetes Care. 2001;24(Suppl 1):S1-S133.
15. Rosenstock J, Samols E, Muchmore DB, Schneider J, for the Glimepiride Study Group. Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Diabetes Care. 1996;19:1194-1199.
16. Sonnenberg GE, Garg DC, Weidler DJ, et al. Short-term comparison of once- versus twice-daily administration of glimepiride in patients with non-insulin-dependent diabetes mellitus. Ann Pharmacother. 1997;31:671-676.
17. Campbell RK Glimepiride: Role of a new sulfonylurea in the treatment of type2 diabetes mellitus. Ann Pharmacother. 1998;32:1044-1052.
18. Dills DG, Schneider J, for the Glimepiride/Glyburide Research Group. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study Horm Metab Res. 1996;28:426-429.
19. Draeger KE, Wernicke-Panten K, Lomp HJ, et al. Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): A double-blind comparison with glibenclamide. Horm Metab Res. 1996;28:419-425.
20. Goldberg RB, Holvey SM, Schneider J, for the Glimepiride Protocol #201 Study Group. A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. Diabetes Care. 1996;19:849-856.
21. Riddle MC, Schneider J, for the Glimepiride Combination Group. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Diabetes Care. 1998;21:1052-1057.
22. Schade DS, Jovanovic L, Schneider J. A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful. J Clin Pharmacol. 1998;38:636-641.
23. Tsumura KI. Clinical evaluation of glimepiride (HOE490) in NIDDM, including a double blind comparative study versus gliclazide. Diabetes Res Clin Pract. 1995;28(Suppl): 5147-5149.
24. Riddle M, McDaniel P, Bugos C. First-dose C-peptide response and risk of hypoglycemia are lower with glimepiride than glyburide. Diabetes [serial online]. 2001;50(Suppl 2). Abstract. Available at: http://www.diabetes.org/am01/AnnualMeeting/AbstractSearch.asp. Accessed June 25, 2001.
25. Draeger E. Clinical profile of glimepiride. Diabetes Res Clin Pract. 1995;28(Suppl): S139-S146.
26. Geisen K, Végh Á, Krause E, Papp JG. Cardiovascular effects of conventional sulfonylureas and glimepiride. Horm Metab Res. 1996;28:496-507.
27. Mocanu MM, Baxter GF, Lawrence CL, et al. The sulfonylurea glimepiride does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation. 2000;102(Suppl II):288. Abstract.
28. Hazuda HP, Comeaux PJ, Stern MP, et al. A comparison of three indicators for identifying Mexican-Americans in epidemiological research. Methodological findings from the San Antonio Heart Study. Am J Epidemiol. 1986;123:96-112.
29. Herrera CR, Lewin A, Fiddes R, et al. Long-acting diltiazem CD is safe and effective in a hypertensive Mexican-American population. Pharmacotherapy. 1997;17:1254-1259.
30. Burritt MF, Klee GG, Hanson E, et al. Evaluation of the One Touch glucose meter for use by a phlebotomy team. Lab Med. 1990;21:512-516.
31. One Touch Test Strips for Blood Glucose Testing [package insert]. Milpitas, Calif: LifeScan Inc; 1999.
32. One Touch Basic Blood Glucose Monitoring System, Owner's Booklet. Milpitas, Calif: LifeScan Inc; 1996.
33. Marbury T, Huang WC, Strange P, Lebovitz H. Repaglinide versus glyburide: A one-year comparison trial. Diabetes Res Clin Pract. 1999;43:155-166.
34. Sinagra D, Scarpitta AM, Amato M. Effects of insulin-oral hypoglycemic agents combined therapy in outpatients with type 2 diabetes. Eur Rev Med Pharmacol Sci. 1998;2:175-179.
35. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ. 1995;310:83-88.
36. Haffner SM, Stern MP, Hazuda HP, et al. Upper body and centralized adiposity in Mexican Americans and non-Hispanic whites: Relationship to body mass index and other behavioral and demographic variables. Int J Obes. 1986;10:493-502.
37. Sundquist J, Winkleby M. Country of birth, acculturation status and abdominal obesity in a national sample of Mexican-American women and men. Int J Epidemiol. 2000;29:470-477.
38. Bittar N. Maintaining long-term control of blood pressure: The role of improved compliance. Clin Cardiol. 1995;18(Suppl 3):III 12-6.
39. Pullar T, Birtwell AJ, Wiles PG, et al. Use of a pharmacologic indicator to compare compliance with tablets prescribed to be taken once, twice, or three times daily. Clin Pharmacol Ther. 1988;44:540-545.
40. Eisen SA, Miller DK, Woodward RS, et al. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med. 1990;150:1881-1884.